Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Sathvik B Sridhar"'
Autor:
Chun-Wai Mai, Sathvik B Sridhar, Mohammed Salim Karattuthodi, Perishithaa M Ganesan, Javedh Shareef, E Lyn Lee, Keivan Armani
Publikováno v:
BMJ Open, Vol 14, Iss 11 (2024)
Introduction Pharmacogenomic testing (PGx) plays a crucial role in improving patient medication safety, yet ethical concerns and limitations impede its clinical implementation in the primary care settings.Aims To systematically review the current sta
Externí odkaz:
https://doaj.org/article/e21c87099bb1443a88eb33fe9aa166f9
Publikováno v:
Journal of Nephropharmacology, Vol 13, Iss 2, Pp e11674-e11674 (2024)
Hyponatremia is a common electrolyte abnormality in chronic kidney disease (CKD). Managing severe hyponatremia in CKD is challenging, requiring the correction of biochemical imbalances and fluid overload, often through traditional hemodialysis. Howev
Externí odkaz:
https://doaj.org/article/b853240e36da425395ddf44b33cd9d90
Publikováno v:
SAGE Open Medicine, Vol 12 (2024)
Introduction: Healthcare professionals’ awareness of adverse drug reaction reporting and pharmacovigilance practices differ by country. The study assesses healthcare professionals’ knowledge, practice, and potential barriers to pharmacovigilance-
Externí odkaz:
https://doaj.org/article/75a10f5d99a34b2fab71fd422d1061c9
Publikováno v:
Journal of Pharmacy and Bioallied Sciences, Vol 12, Iss 2, Pp 131-138 (2020)
Background: Antidepressant medications are primarily used in the management of depression and various anxiety disorders. Antidepressant medications are known to cause adverse drug reactions (ADRs). Reporting ADRs can help in the rational use of medic
Externí odkaz:
https://doaj.org/article/9451faec0370459ca759fb568b866833
Publikováno v:
Journal of Pharmacy and Bioallied Sciences, Vol 11, Iss 2, Pp 148-154 (2019)
Objective: Hyperphosphatemia in end-stage renal disease (ESRD) is associated with many serious patient-level consequences including cardiovascular events and mortality. The purpose of this study was to investigate the use of phosphate binders in ESRD
Externí odkaz:
https://doaj.org/article/7f690025821f4c66a8f474f3b92d12ad
Publikováno v:
Archives of Pharmacy Practice, Vol 4, Iss 3, Pp 133-136 (2013)
Objectives: Internationally, the role of pharmacist has now been extended from the provision of traditional services to patient specific care services. Unlike other developed countries, clinical pharmacy services are very rare in the health care sett
Externí odkaz:
https://doaj.org/article/7907263bf8894a36b255eb2e79a3ab59
Autor:
Syed Arman Rabbani, Sathvik B. Sridhar, Maryam Safdar, Padma G. M. Rao, Ammar Ali Saleh Jaber, Mohammad M. AlAhmad, Khaled Shaar, Israa Emad, Muhammad Abdul Azim
Publikováno v:
Medicina; Volume 59; Issue 5; Pages: 843
Background and Objectives: Overprescribing of antibiotics is one of the important contributors of antimicrobial resistance globally. A high proportion of antibiotics prescribed in community settings are unnecessary or inappropriate. This study assess
Publikováno v:
Tropical Journal of Pharmaceutical Research; Vol. 21 No. 4 (2022); 853-861
Purpose: To determine the prevalence and assessing nature of potential drug-drug interactions (pDDIs) and adverse drug reactions (ADRs) among chronic kidney disease (CKD) patients.Methods: This was a prospective observational study involving adult CK
Autor:
Mullaicharam Bhupathyraaj, K. Reeta Vijaya Rani, Sathvik B. Sridhar, Javed Shareef, Sabin Thomas, Nirmala Halligudi, Anbazhagan Sockalingam, Kiruba Mohandoss, Shyam Sundar
Publikováno v:
Polymers; Volume 14; Issue 10; Pages: 1984
Quetiapine Fumarate is potent, and the daily therapeutic dose can be delivered easily across the skin with the help of permeation enhancers. Quetiapine Fumarate-loaded transdermal patches were prepared by solvent evaporation technique. Various formul
Publikováno v:
Cureus. 14(4)
Background Chronic kidney disease (CKD) is a challenging global health problem with increasing prevalence worldwide. Concurrence of CKD and comorbidities results in the use of multiple medications and exposing patients to polypharmacy. Polypharmacy i